---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-010258"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T14:17:18.193645+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO

## Summary
- CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.
- Separation benefits: 12-month base salary, 2022 target bonus, 24 months COBRA, full equity vesting.
- Eligible for $135k in performance bonuses under 2022 ERB-Plan, including $67.5k for transition assistance.
- Donegan continues as Principal Financial Officer and Principal Accounting Officer in consulting capacity.

## SEC filing metadata
- accession: 0001193125-23-010258
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/0001193125-23-010258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/d399403d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-010258
- JSON: https://secwatch.observer/filing/0001193125-23-010258.json
- Plain text: https://secwatch.observer/filing/0001193125-23-010258.txt

## Key facts
- Executive change
  Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..
  - Action: terminated
  - Role: Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance
  source text: Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/0001193125-23-010258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.